Crosstalk between Human IgG Isotypes and Murine Effector Cells
暂无分享,去创建一个
P. Parren | S. Verploegen | J. Leusen | W. Bleeker | T. Vink | M. Overdijk | Antonio Ortiz Buijsse | A. Ortiz Buijsse
[1] C. Conner. Therapy with Monoclonal Antibodies , 1984, Drug intelligence & clinical pharmacy.
[2] M. Neuberger,et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.
[3] J. Ghrayeb,et al. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[4] S L Morrison,et al. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.
[5] C. Anderson,et al. Biology of Human Immunoglobulin G Fc Receptors , 1991, Journal of leukocyte biology.
[6] J. Isaacs,et al. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. , 1992, Journal of immunology.
[7] P. Parren,et al. On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. , 1992, The Journal of clinical investigation.
[8] P. Parren,et al. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. , 1992, Journal of immunology.
[9] A. Lawson,et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. , 1993, Molecular immunology.
[10] M. Glennie,et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. , 1996, Blood.
[11] M. Madanat,et al. Intrachain disulfide bond in the core hinge region of human IgG4 , 1997, Protein science : a publication of the Protein Society.
[12] C. Kallenberg,et al. Inflammation in autoimmunity: receptors for IgG revisited. , 2001, Trends in immunology.
[13] R. Ober,et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.
[14] R. Aalberse,et al. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. , 2001, Molecular immunology.
[15] T. Valerius,et al. Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity1 , 2002, The Journal of Immunology.
[16] P. Parren,et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.
[17] P. Parren,et al. Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy , 2004, The Journal of Immunology.
[18] J. Ravetch,et al. Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.
[19] P. Bruhns,et al. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. , 2005, Immunity.
[20] Robin Shattock,et al. In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.
[21] Shigeru Iida,et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. , 2005, Journal of immunological methods.
[22] R. Herrmann,et al. Overview of monoclonal antibodies in cancer therapy: present and promise. , 2005, Critical reviews in oncology/hematology.
[23] P. Bruhns,et al. FcγRIV : A novel FcR with distinct IgG subclass specificity , 2005 .
[24] J. Leusen,et al. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. , 2006, Cancer research.
[25] P. Carter. Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.
[26] P. Parren,et al. Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.
[27] M. Pallardy,et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. , 2007, Critical reviews in oncology/hematology.
[28] Tomoaki Nakagawa,et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. , 2008, Cancer research.
[29] J. Ravetch,et al. Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.
[30] J. Ravetch,et al. Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.
[31] B. Nieswandt,et al. Both FcγRIV and FcγRIII are essential receptors mediating type II and type III autoimmune responses via FcRγ‐LAT‐dependent generation of C5a , 2009, European journal of immunology.
[32] P. Parren,et al. Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage , 2009, The Journal of Immunology.
[33] N. Van Rooijen,et al. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40 , 2008, British Journal of Cancer.
[34] P. Bruhns,et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.
[35] K. Lewis,et al. Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4)in vitro and in vivo. , 2009, Molecular immunology.
[36] J. Ravetch,et al. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo , 2010, Proceedings of the National Academy of Sciences.
[37] I. Jónsdóttir,et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential , 2011, Nature communications.
[38] P. Parren,et al. Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition , 2011, The Journal of Immunology.
[39] P. Parren,et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden , 2011, Haematologica.